longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Kiniksa Pharmaceuticals

KNSA

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is 73.98, within the reasonable range, cheaper than 54.79% of the time in the past 1 years, and the industry ranks 55/600, the industry Median -2.56.

73.98xP/E
$76.48Stock price
$1.03Earnings per share
73.98xP/E
Stock price$76.48Earnings per share$1.03

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
75.37x
Typical range
59.69x–91.16x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
019385776

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
P/E ratio
Name/Symbol
ABBVUSAbbvie
71.87x230.92%$450.61B
CAIUSCaris Life Sciences
64.62x132.37%$6.79B
KNSAUSKiniksa Pharmaceuticals
73.98x68.27%$5.97B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.